BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

Core Insights - BeiGene, Ltd. is presenting emerging oncology pipeline data at the AACR Annual Meeting, showcasing its commitment to developing innovative cancer treatments [1][2][7] - The company has nine abstracts scheduled for poster presentations, focusing on various combinations of tislelizumab and other novel candidates [1][2] Pipeline Developments - Results from the AdvanTIG-204 Phase 2 study of tislelizumab plus ociperlimab in limited-stage small cell lung cancer (SCLC) will be presented, along with biomarker study results in first-line non-small cell lung cancer (NSCLC) [1][2] - An ongoing global Phase 3 trial (AdvanTIG-302) of ociperlimab plus tislelizumab in stage IV, PD-L1 high NSCLC is set to complete enrollment this month [1] - A Phase 1a dose escalation study of BGB-10188, a PI3Kδ inhibitor, in combination with tislelizumab will also be presented [1][2] Novel Molecules and Combinations - Preclinical characterizations of several novel molecules, including a CEA x 4-1BB bispecific antibody and a chimeric degradation activation compound (CDAC) targeting BTK, will be showcased [2] - Clinical data from a Phase 1 study of BGB-16673 in relapsed/refractory B-cell malignancies demonstrated clinical responses and a tolerable safety profile [2] - A triple-combination therapy of tislelizumab with anti-LAG-3 and anti-TIM-3 is being evaluated in a Phase 2 study for head and neck squamous cell carcinoma [2] Presentation Schedule - The presentations will cover various studies, including the correlation between BTK degradation and tumor growth inhibition, and the efficacy of ociperlimab plus tislelizumab in NSCLC [3][4] - Specific abstracts include a first-in-human Phase 1a study of BGB-10188 and a Phase 2 study evaluating LBL-007 in combination with tislelizumab [4][5][6] Company Overview - BeiGene is focused on discovering and developing affordable and accessible cancer treatments globally, with a diverse pipeline of novel therapeutics [7] - The company has a global team of over 10,000 employees and operates in multiple regions, including Basel, Beijing, and Cambridge [7]